Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans

Pharmacogenetics

Volumn 12, Issue 7, 2002, Pages 535-541

  Vogelgesang, Silke ^a   Cascorbi, Ingolf ^a   Schroeder, Eike ^a   Pahnke, Jens ^a   Kroemer, Heyo K ^a   Siegmund, Werner ^a   Kunert Keil, Christiane ^a   Walker, Lary C ^a   Warzok, Rolf W ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

amyloid; Ageing; Alzheimer's disease; Apolipoprotein E; MDR1; Neurodegeneration; P glycoprotein; Proteopathy; Vascular endothelium

Indexed keywords

ABC TRANSPORTER; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; NERVE DEGENERATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RISK FACTOR; SENILE PLAQUE; TEMPORAL LOBE; VASCULAR ENDOTHELIUM;

AGED; AGED, 80 AND OVER; AGING; ALLELES; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; AUTOPSY; BRAIN; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REFERENCE VALUES;

EID: 0036797713     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200210000-00005     Document Type: Article

References (33)

1. Walker LC, LeVine HL. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol Neurobiol 2000; 21:83-95.
2. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999; 399:A23-A31.
3. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106:1489-1499.
4. Lam FC, Liu R, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB. β-amyloid efflux mediated by p-glycoprotein. J Neurochem 2001; 76:1121-1128.
5. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-162.
6. Fromm MF, Kaufmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157:1575-1580.
7. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000; 38:69-74.
8. Schinkel AH. The physiological function of drug transporting P-glycoproteins. Semin Cancer Biol 1997; 8:161-170.
9. Zhang Y, Benet LZ. The gut as a barrier to drug absorption. Combined role of cytochrome P4503A and P-glycoprotein. Clin Pharmacokinet 2001; 40:159-168.
10. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147-153.
11. Westphal K, Weinbrenner A, Gießmann T, Stuhr M, Franke G, Zschiesche M, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000; 68:6-12.
12. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, et al. Induction of p-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000; 68:345-355.
13. Johne A, Brockmoeller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66:338-345.
14. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99:552-557.
15. Gramatté T, Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 1999; 66:239-245.
16. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174.
17. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller Johne A, Cascorbi I, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
18. Demeule M, Labelle M, Regina A, Berthelet F, Beliveau R. Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P- glycoprotein isoforms. Biochem Biophys Res Commun 2001; 281:827-834.
19. Golden PL, Pardridge WM. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 2000; 20:165-181.
20. Miller DS, Mobmann SN, Gutmann H, Toeroek M, Drewe J, Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 2000; 58:1357-1367.
21. Walker LC, Pahnke J, Madauβ M, Vogelgesang S, Pahnke A, Herbst EW, et al. Apolipoprotein E4 promotes the early deposition of Aβ42 and then Aβ40 in the elderly. Acta Neuropathol 2000; 100:36-42.
22. Warzok R, Kessler C, Apel G, Schwarz A, Egensperger R, Schreiber D, et al. Apolipoprotein E promotes incipient Alzheimer pathology in the elderly. Alzheimer Dis Relat Dis 1998; 12:33-39.
23. Selkoe DJ. Towards a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein. Ann NY Acad Sci 2000; 924:17-25.
24. Croop JM. Evolutionary relationships among ABC transporters. Methods Enzymol 1998; 292:101-117.
25. Terzi E, Holzemann G, Seelig J. Interaction of Alzheimer β-amyloid peptide (1-40) with lipid membranes. J Biochem 1997; 36:14845-14852.
26. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today 2001; 6:835-839.
27. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene J Pharmacol Exp Ther 2001; 297:1137-1143.
28. Corder EH, Lannfelt L, Bogdanovic N, Fratiglioni L, Mori H. The role of ApoE polymorphism in late-onset dementias. Cell Mol Life Sci 1998; 54:928-934.
29. ε4 with late onset familial and sporadic Alzheimer's disease. Neurology 1993; 43:1467-1472.
30. Doze P, van Waarde A, Elsinga PH, Hendrikse NH, Vaalburg W. Enhanced cerebral uptake of receptor ligands by modulation of p-glycoprotein function in the blood-brain barrier. Synapse 2000; 36:66-74.
31. Fassbender K, Simons M, Bergmann C, Stroick M, Lütjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98:5856-5861.
32. Bogman K, Peyer A-K, Török M, Küsters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132:1183-1192.
33. Hooiveld GJEJ, Vos TA, Scheffer GL, van Goor H, Koning H, Bloks V, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 1999; 117:678-687.